Reference
Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib) - Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi). Internet Document : 22 Mar 2023. Available from: URL: https://www.hpra.ie/homepage/medicines/safety-notices/item?t=/cibinqo-(abrocitinib)-jyseleca-(filgotinib)-olumiant-(baricitinib)-rinvoq-(upadacitinib)-and-xeljanz-(tofacitinib)---important-safety-information-from-marketing-authorisation-holders-of-these-products-as-approved-by-the-hpra-(13.03.2023)&id=a7f81326-9782-6eee-9b55-ff00008c97d0
Rights and permissions
About this article
Cite this article
JAK inhibitor safety information updated with risk minimisation measures. Reactions Weekly 1951, 2 (2023). https://doi.org/10.1007/s40278-023-36779-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-36779-0